Skip to content
Markets News
Stocks1 min read

ResMed’s Growth Outlook Trails Its Recent Revenue Pace

Makkler Newsroom
October 5, 2026

StockStory points to ResMed’s cash generation as a strength, while analysts expect slower revenue growth over the next 12 months.

Key takeaways

  • ResMed’s constant-currency revenue grew by an average of 8.9% annually over two years.
  • Analysts expect revenue to rise 2.7% over the next 12 months, according to StockStory.

ResMed shares were quoted at $218.94 in StockStory’s analysis, down 2.7% over six months, while the S&P 500 gained 15.9%. In Monday afternoon trading, the stock was $223.35, up 2.04% since the previous close.

StockStory highlighted ResMed’s average 8.9% annual growth in constant-currency revenue over the past two years. It also noted the company’s trailing 12-month free cash flow margin was 29.2%.

Wall Street analysts expect revenue to grow 2.7% over the next 12 months, below the 12.1% annualized rate of the past five years, according to StockStory. The article cited a forward price-to-earnings ratio of 18.2 at its $218.94 share price.

Topics
Further reading

This article was produced with the help of AI technology. Based on reporting by the outlets listed above.

Comments (0)

Log in to join the discussion.Log in

No comments yet - be the first to weigh in.